Usefulness of Antimicrobial Prophylaxis in Children With Isolated Vesico-Ureteral Reflux.

This study has been completed.
Sponsor:
Information provided by:
Nantes University Hospital
ClinicalTrials.gov Identifier:
NCT00200616
First received: September 12, 2005
Last updated: June 30, 2008
Last verified: June 2008
  Purpose

Randomized, prospective, multicenter study in order to assess the usefulness of antimicrobial prophylaxis in children with isolated vesico-ureteral reflux (grade III or less).


Condition Intervention
Urinary Tract Infection
Procedure: Antimicrobial prophylaxis

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Antimicrobial Prophylaxis in Children With Isolated Vesico-Ureteral Reflux. A Randomised Prospective Study of Continuous Low Dose of Trimethoprim-Sulfamethoxazole Versus Surveillance.

Resource links provided by NLM:


Further study details as provided by Nantes University Hospital:

Primary Outcome Measures:
  • End point : recurrence of urinary tract infection during the study period (0 è 18 months)

Secondary Outcome Measures:
  • 1) Type of urinary tract infection (pyelonephritis or cystitis)
  • 2) Evaluation of the quality of life with a validated questionnaire done at 9 months

Estimated Enrollment: 232
Study Start Date: April 2001
Study Completion Date: July 2006
Primary Completion Date: July 2006 (Final data collection date for primary outcome measure)
Detailed Description:

A voiding cystourethrogram was performed for each child less than 3 years old with a first urinary tract infection. In case of vesico-ureteral reflux, a randomization was done between continuous antimicrobial prophylaxis with low dose of trimethoprim-sulfamethoxazole and no antibioprophylaxis. Duration of follow up was 18 months.

  Eligibility

Ages Eligible for Study:   up to 3 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Children less than 3 years old
  • First proved urinary tract infectionIsolated vesico-ureteral reflux
  • Parents have been fully informed and have given written informed consent to participate in the study

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00200616

Locations
France
Nantes University Hospital
Nantes, France
Sponsors and Collaborators
Nantes University Hospital
Investigators
Principal Investigator: Claude GUYOT, MD Nantes University Hospital
  More Information

No publications provided

Responsible Party: Claude GUYOT, Nantes University Hospital
ClinicalTrials.gov Identifier: NCT00200616     History of Changes
Other Study ID Numbers: BRD/00/10-O
Study First Received: September 12, 2005
Last Updated: June 30, 2008
Health Authority: France: Ministry of Health

Keywords provided by Nantes University Hospital:
Urinary tract infection
Vesico-renal reflux
Child
Antimicrobial prophylaxis
Recurrence of urinary tract infection

Additional relevant MeSH terms:
Infection
Communicable Diseases
Urinary Tract Infections
Vesico-Ureteral Reflux
Urologic Diseases
Urinary Bladder Diseases
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 16, 2014